SG Americas Securities’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-11,497
| Closed | -$27K | – | 3680 |
|
|
2025
Q3 | $27K | Buy |
+11,497
| New | +$22K | ﹤0.01% | 3262 |
|
|
2025
Q2 | – | Sell |
-11,778
| Closed | -$19K | – | 3253 |
|
|
2025
Q1 | $19K | Buy |
11,778
+958
| +9% | +$1.92K | ﹤0.01% | 3382 |
|
|
2024
Q4 | $20K | Sell |
10,820
-1,466
| -12% | -$6.49K | ﹤0.01% | 3012 |
|
|
2024
Q3 | $71K | Buy |
+12,286
| New | +$101K | ﹤0.01% | 3167 |
|
|
2023
Q2 | – | Sell |
-8,006
| Closed | -$79K | – | 2702 |
|
|
2023
Q1 | $79K | Buy |
8,006
+7,023
| +714% | +$120K | ﹤0.01% | 2981 |
|
|
2022
Q4 | $18K | Sell |
983
-4,968
| -83% | -$113K | ﹤0.01% | 2943 |
|
|
2022
Q3 | $123K | Sell |
5,951
-21,797
| -79% | -$558K | ﹤0.01% | 2694 |
|
|
2022
Q2 | $576K | Buy |
27,748
+25,214
| +995% | +$711K | 0.01% | 1843 |
|
|
2022
Q1 | $109K | Sell |
2,534
-2,201
| -46% | -$99.1K | ﹤0.01% | 2733 |
|
|
2021
Q4 | $284K | Sell |
4,735
-9,493
| -67% | -$761K | ﹤0.01% | 2475 |
|
|
2021
Q3 | $1.22M | Buy |
14,228
+13,319
| +1,465% | +$1.34M | 0.01% | 1725 |
|
|
2021
Q2 | $101K | Sell |
909
-2,131
| -70% | -$205K | ﹤0.01% | 2675 |
|
|
2021
Q1 | $339K | Sell |
3,040
-192
| -6% | -$25.3K | ﹤0.01% | 2289 |
|
|
2020
Q4 | $343K | Sell |
3,232
-3,039
| -48% | -$405K | ﹤0.01% | 2270 |
|
|
2020
Q3 | $873K | Buy |
6,271
+3,331
| +113% | +$695K | 0.01% | 1265 |
|
|
2020
Q2 | $951K | Buy |
2,940
+198
| +7% | +$31.8K | 0.01% | 1463 |
|
|
2020
Q1 | $245K | Sell |
2,742
-4,471
| -62% | -$276K | ﹤0.01% | 2366 |
|
|
2019
Q4 | $286K | Buy |
7,213
+1,476
| +26% | +$44.4K | ﹤0.01% | 2229 |
|
|
2019
Q3 | $141K | Buy |
+5,737
| New | +$174K | ﹤0.01% | 2545 |
|
|
2019
Q2 | – | Sell |
-889
| Closed | -$40K | – | 3250 |
|
|
2019
Q1 | $40K | Buy |
+889
| New | +$44.8K | ﹤0.01% | 3227 |
|
|
2018
Q3 | – | Sell |
-881
| Closed | -$41K | – | 3298 |
|
|
2018
Q2 | $41K | Buy |
+881
| New | +$48.6K | ﹤0.01% | 3196 |
|
|
2017
Q4 | – | Sell |
-1,350
| Closed | -$103K | – | 3406 |
|
|
2017
Q3 | $103K | Buy |
1,350
+475
| +54% | +$35.3K | ﹤0.01% | 3182 |
|
|
2017
Q2 | $82K | Buy |
+875
| New | +$74.8K | ﹤0.01% | 2960 |
|
|
2016
Q4 | – | Sell |
-1,590
| Closed | -$178K | – | 3294 |
|
|
2016
Q3 | $178K | Buy |
+1,590
| New | +$176K | ﹤0.01% | 2595 |
|
|
2016
Q2 | – | Sell |
-907
| Closed | -$95K | – | 2796 |
|
|
2016
Q1 | $95K | Buy |
+907
| New | +$70K | ﹤0.01% | 2637 |
|
|
2015
Q1 | – | Sell |
-1,220
| Closed | -$134K | – | 2790 |
|
|
2014
Q4 | $134K | Buy |
+1,220
| New | +$149K | ﹤0.01% | 2727 |
|
|
2014
Q3 | – | Sell |
-1,118
| Closed | -$145K | – | 2735 |
|
|
2014
Q2 | $145K | Sell |
1,118
-1,495
| -57% | -$176K | ﹤0.01% | 2197 |
|
|
2014
Q1 | $418K | Buy |
+2,613
| New | +$375K | ﹤0.01% | 1577 |
|
Other funds holding INO
BCM
ACM
SG Americas Securities's INO Position: Q4 2025 in Review
SG Americas Securities sold out of Inovio Pharmaceuticals (INO) in Q4 2025, closing a stake of 11,497 shares — an estimated $27K sold.
SG Americas Securities first reported a position in INO in Q1 2014 and held it in 28 quarters. The position peaked at $1.22M in Q3 2021. 102 funds tracked by Wall St. Rank hold INO as of Q4 2025.
- SG Americas Securities reported no remaining Inovio Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- SG Americas Securities sold 11,497 Inovio Pharmaceuticals shares in Q4 2025, an estimated $27K.
- SG Americas Securities first reported a position in Inovio Pharmaceuticals in Q1 2014 and held it in 28 quarters.
- SG Americas Securities's Inovio Pharmaceuticals position peaked at $1.22M in Q3 2021.
- 102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2025.
Based on SG Americas Securities's 13F filing for Q4 2025, filed 9 Jan 2026.